CeriBell, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium. Speak
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium. Speak
CeriBell, Inc. (CBLL) Bank of America Global Healthcare Conference 2026 May 13, 2026 6:40 PM EDTCompany ParticipantsXingjuan Chao - Co-Founder, President,...
Presenter SpeechXingjuan Chao Thank you for having us.AnswerUnknown Attendee Maybe we can start with Q1 since you just reported the other day, revenue came in a little better than the Street, and
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $28 to $25.
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call May 11, 2026 4:30 PM EDTCompany ParticipantsXingjuan Chao - Co-Founder, President, CEO & DirectorScott...
CeriBell Inc (CBLL) reports impressive revenue growth and market expansion, despite facing increased operating expenses and litigation costs.
CeriBell Inc (CBLL) reports impressive revenue growth and market expansion, despite facing increased operating expenses and litigation costs.
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder
Earlier today, CeriBell, Inc. issued a press release announcing financial results for the quarter ended 03/31/2026. Beyond continued progress in penetrating our core seizure market, we delivered two major milestones that mark inflection points in the evolution of our platform.
Earlier today, CeriBell, Inc. issued a press release announcing financial results for the quarter ended 03/31/2026. Beyond continued progress in penetrating our core seizure market, we delivered two major milestones that mark inflection points in the evolution of our platform.
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of -32.48% and +1.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of -32.48% and +1.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Presentation Operator MessageOperator Thank you for standing by. At this time, I would like to welcome everyone to the Ceribell First Quarter 2026 Earnings Call. [Operator Instructions] Thank you.
Ceribell Q1 revenue beat estimates at $26.5M, but net loss widened to $19.7M on higher legal costs. Full-year guidance raised to $112M–$116M amid pediatric product launch and strong account growth.
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025Ended the quarter with 680 total act
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.000 million-$116.000 million vs $113.138 million estimate.
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 44.44 percent decrease over losses of $(0.36) per share from the
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 4.85M | $88.91M | 0.00% | Added+23.5% | 2026-03-31 |
| StateStreet | passive | 525.4K | $9.63M | 0.00% | Added+11.3% | 2026-03-31 |
| TwoSigma | quant | 326.0K | $5.98M | 0.00% | Trimmed-5.1% | 2026-03-31 |
| DEShaw | quant | 84.7K | $1.55M | 0.00% | New | 2026-03-31 |
| Wellington | fundamental | 83.1K | $1.52M | 0.00% | New | 2026-03-31 |
| Citadel | multi-strat | 77.7K | $1.42M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 18.2K | $335 | 0.00% | Added+21.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -0.46 | — | — |
| 2026-05-11 | -0.39 | -0.38 | +3.62% |
| 2026-02-24 | -0.41 | -0.36 | +12.65% |
| 2025-11-04 | -0.41 | -0.37 | +10.63% |
| 2025-08-05 | -0.40 | -0.38 | +4.64% |
| 2025-05-08 | -0.46 | -0.36 | +21.17% |
| 2025-02-25 | -0.31 | -0.40 | -27.48% |
| 2024-11-12 | -0.87 | -1.85 | -113.24% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CBLL | -10.00% | +5.19% | -15.87% | +9.76% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -12.97% | +9.83% | -12.43% | -2.93% |